Dali Pharmaceutical Co Ltd
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection. The company's products include xingnaojing, shenmai, and astragalus injections, as well as citicoline injections. It also has patents, including invention patents and utility models. The company was founded in 1996 and is headquartered in Dali,… Read more
Dali Pharmaceutical Co Ltd - Asset Resilience Ratio
Dali Pharmaceutical Co Ltd (603963) has an Asset Resilience Ratio of 17.49% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how Dali Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Dali Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥80.78 Million | 17.49% |
| Total Liquid Assets | CN¥80.78 Million | 17.49% |
Asset Resilience Insights
- Good Liquidity Position: Dali Pharmaceutical Co Ltd maintains a healthy 17.49% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Dali Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Dali Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
High Sierra Technologies Inc
PINK:HSTI |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
Annual Asset Resilience Ratio for Dali Pharmaceutical Co Ltd (2012–2023)
The table below shows the annual Asset Resilience Ratio data for Dali Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 43.63% | CN¥206.74 Million | CN¥473.83 Million | -1.90pp |
| 2022-12-31 | 45.53% | CN¥229.23 Million | CN¥503.49 Million | +21.39pp |
| 2021-12-31 | 24.14% | CN¥132.44 Million | CN¥548.75 Million | -17.46pp |
| 2020-12-31 | 41.60% | CN¥240.75 Million | CN¥578.71 Million | +1.48pp |
| 2019-12-31 | 40.12% | CN¥225.23 Million | CN¥561.33 Million | +2.25pp |
| 2018-12-31 | 37.88% | CN¥225.19 Million | CN¥594.51 Million | -0.36pp |
| 2017-12-31 | 38.24% | CN¥234.30 Million | CN¥612.76 Million | +33.72pp |
| 2016-12-31 | 4.52% | CN¥13.17 Million | CN¥291.45 Million | -15.44pp |
| 2014-12-31 | 19.96% | CN¥71.58 Million | CN¥358.68 Million | +17.11pp |
| 2013-12-31 | 2.84% | CN¥10.00 Million | CN¥351.62 Million | -3.52pp |
| 2012-12-31 | 6.36% | CN¥19.00 Million | CN¥298.58 Million | -- |